{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:50:12Z","timestamp":1792759812042,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,6,23]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14 while patients initially randomised to upadacitinib continued their regimen through week 104. Efficacy was assessed using as-observed (AO) and non-responder imputation (NRI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 187 patients randomised, 144 patients (77%) completed week 104. Among patients receiving continuous upadacitinib, 85.9% (AO) and 65.6% (NRI) achieved Assessment of SpondyloArthritis international Society 40 response (ASAS40) at week 104. Similar magnitude of ASAS40 responses were observed among patients who switched from placebo to upadacitinib (88.7% and 63.8%, respectively). The mean change from baseline to week 104 in Spondyloarthritis Research Consortium of Canada MRI spine and sacroiliac joint inflammation scores were \u20137.3 and \u20135.3, respectively, in the continuous upadacitinib group and \u20137.9 and \u20134.9 in the placebo-to-upadacitinib switch group. The mean (95% CI) change from baseline to week 104 in the modified Stoke Ankylosing Spondylitis Spine Score was 0.7 (0.3, 1.1) in the total group. Adverse event rate was 242.7\/100 patient-years. No serious infections, adjudicated major adverse cardiovascular events, lymphoma, non-melanoma skin cancer, or gastrointestinal perforations were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 2 years for ASAS40 and other clinically relevant endpoints. A low rate of radiographic progression was observed and no new safety findings were observed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002280","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:52:21Z","timestamp":1658973141000},"page":"e002280","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03178487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-9890","authenticated-orcid":false,"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectious Diseases and Rheumatology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3542-2276","authenticated-orcid":false,"given":"Tae-Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University, School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4827","authenticated-orcid":false,"given":"Andrew J","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[{"name":"Cabrini Medical Centre and Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Sui","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Duan","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K","family":"Wung","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ho","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"2025090313280905000_8.2.e002280.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2025090313280905000_8.2.e002280.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203582"},{"key":"2025090313280905000_8.2.e002280.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090313280905000_8.2.e002280.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090313280905000_8.2.e002280.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322"},{"key":"2025090313280905000_8.2.e002280.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"2025090313280905000_8.2.e002280.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"2025090313280905000_8.2.e002280.8","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. new players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"2025090313280905000_8.2.e002280.9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025090313280905000_8.2.e002280.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"2025090313280905000_8.2.e002280.11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090313280905000_8.2.e002280.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"2025090313280905000_8.2.e002280.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2025090313280905000_8.2.e002280.14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.38921","article-title":"Calculating the Ankylosing Spondylitis Disease Activity Score if the conventional C-reactive protein level is below the limit of detection or if high-sensitivity C-reactive protein is used: an analysis in the DESIR cohort","volume":"67","author":"Machado","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313280905000_8.2.e002280.15","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090313280905000_8.2.e002280.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21337"},{"key":"2025090313280905000_8.2.e002280.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21445"},{"key":"2025090313280905000_8.2.e002280.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"2025090313280905000_8.2.e002280.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2025090313280905000_8.2.e002280.20","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-021-01001-1","article-title":"JAK inhibitors for axial spondyloarthritis: what does the future hold?","volume":"23","author":"Akkoc","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313280905000_8.2.e002280.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"2025090313280905000_8.2.e002280.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"2025090313280905000_8.2.e002280.23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313280905000_8.2.e002280.24","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"2025090313280905000_8.2.e002280.25","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-eular.1620","article-title":"POS0918 evaluation of spinal radiographic progression in patients with radiographic axial spondyloarthritis receiving ixekizumab therapy over 2 years","volume":"80","author":"Van der Heijde","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090313280905000_8.2.e002280.26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology"},{"key":"2025090313280905000_8.2.e002280.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210471"},{"key":"2025090313280905000_8.2.e002280.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"2025090313280905000_8.2.e002280.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2025090313280905000_8.2.e002280.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2025090313280905000_8.2.e002280.31","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313280905000_8.2.e002280.32","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2013.834961"},{"key":"2025090313280905000_8.2.e002280.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214388"},{"key":"2025090313280905000_8.2.e002280.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2025090313280905000_8.2.e002280.35","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2"},{"key":"2025090313280905000_8.2.e002280.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02549-0","article-title":"Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials","volume":"23","author":"Roche","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313280905000_8.2.e002280.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210931"},{"key":"2025090313280905000_8.2.e002280.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220420"},{"key":"2025090313280905000_8.2.e002280.39","unstructured":"A study to evaluate efficacy and safety of upadacitinib in adult participants with axial spondyloarthritis (SELECT-AXIS 2). ClinicalTrials.gov identifier: NCT04169373 . Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04169373 [Accessed 31 Aug 2020]."}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:28:21Z","timestamp":1756931301000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,27]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/rmdopen-2022-002280"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002280","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}